Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

472
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
472
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

1.4K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
1.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same author

Lifestyle Program for Breast Cancer Improves Body Composition, Fitness, and Patient-Reported Outcomes: A Randomized Clinical Trial.

Cancers·2026
Same author

Risk of malignancy after diagnosis of radial sclerosing lesion without atypia.

Breast cancer research and treatment·2026
Same author

Active monitoring versus surgical excision for atypical ductal hyperplasia.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Radiation Therapy De-escalation in Breast Cancer Patients With Pathologic Complete Response: An Integrated Analysis Using Real-World and Simulated Data.

International journal of radiation oncology, biology, physics·2026
Same author

Targeting microRNA let-7b-5p-mediated aberrant androgen receptor signaling for prevention of hormone receptor-negative breast cancer.

NPJ breast cancer·2026

Related Experiment Video

Updated: Sep 29, 2025

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.4K

Helping Patients Understand and Cope with BRCA Mutations.

Sukh Makhnoon1, Banu Arun2, Isabelle Bedrosian3

  • 1Department of Behavioral Science, UT MD Anderson Cancer Center, Dan L. Duncan Building, 1515 Holcombe Blvd, Unit 1330, Houston, TX, 77030, USA. smakhnoon@mdanderson.org.

Current Oncology Reports
|March 18, 2022
PubMed
Summary

Individuals with BRCA1/2 gene mutations need specialized support for informed decisions. This review covers strategies and interventions to meet their unique psychosocial and educational needs, improving care for mutation carriers.

Keywords:
BRCA1/2Clinical decision-makingCopingGenetic educationPsychosocial support

More Related Videos

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.8K
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

13.3K

Related Experiment Videos

Last Updated: Sep 29, 2025

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.4K
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

14.8K
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

13.3K

Area of Science:

  • Medical Genetics
  • Psychosocial Support
  • Clinical Communication

Background:

  • Germline mutations in BRCA1/2 confer unique needs for patients.
  • Informed clinical decision-making requires addressing psychosocial and educational aspects.
  • Effective support is crucial for individuals with hereditary cancer predispositions.

Purpose of the Study:

  • To review strategies for supporting patients with BRCA1/2 mutations.
  • To highlight pre- and post-disclosure support interventions.
  • To identify methods for informed clinical decision-making in carriers.

Main Methods:

  • Literature review of clinical practice strategies.
  • Analysis of existing pre- and post-disclosure support interventions.
  • Synthesis of research on risk communication and patient needs.

Main Results:

  • Clinical risk communication faces challenges due to uncertainty and variable intervention effectiveness.
  • Current psychosocial support interventions and risk communication strategies are largely effective.
  • Ongoing research aims to develop new resources, but representation of all carriers remains a challenge.

Conclusions:

  • Effective clinical risk communication, decision aids, educational materials, and psychosocial tools significantly support BRCA carriers.
  • Addressing the unique needs of BRCA mutation carriers is essential for optimal care.
  • Continued development and equitable implementation of support resources are necessary.